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The year 2014 brought a large number of
important advances to cardiovascular medicine
that are likely to impact the field for many
years, if not decades [1]. Herein are our
thoughts on the top stories in 2014 and what
is likely to remain hot in 2015.
In the field of lipids, several studies with
proprotein convertase subtilisin kexin 9
(PCSK9) inhibitors demonstrated their potent
effects to lower low-density-lipoprotein
cholesterol (LDL-C) in a wide variety of
patients. In addition to reducing LDL-C by
50% or more, PCSK9 inhibitors have favorable
effects on apolipoprotein-B, lipoprotein (a), and
triglycerides. Although much less potent than
the PCSK9 inhibitors, the cholesterol
absorption inhibitor ezetimibe became the first
non-statin to demonstrate a reduction in
cardiovascular events on top of background
statin therapy. In the IMPROVE IT trial
(ClinicalTrials.gov NCT 00202878), the addition
of ezetimibe to statin therapy decreased average
LDL from 69.5 to 53.7 mg/dl and reduced
cardiovascular events, without any safety
concerns. Although the benefits were relatively
modest (10% reduction in cardiovascular
death, myocardial infarction (MI), or stroke),
this proof of principle bodes well for PCSK9
inhibitors and other drugs in development that
lower LDL-C by other mechanisms.
In the field of heart failure, a novel approach
that combined an angiotensin receptor blocker
and a neprilysin inhibitor (LCZ696, valsartan/
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sacubitril) demonstrated a 20% reduction in
hospitalization for heart failure or
cardiovascular mortality as compared to
enalapril alone. This landmark study
demonstrated that dual-acting neurohormonal
inhibition further reduced clinical events
beyond that obtained with a single inhibitor
of the renin-angiotensin system, which had
been the gold standard for over 2 decades.
In the world of interventional cardiology
three developments stand out in 2014. An
implantable loop recorder was six times more
likely than conventional monitoring to pick up
atrial fibrillation (the majority of episodes were
asymptomatic) among patients who recently
had an ischemic stroke of unknown etiology,
while a second study confirmed the benefit of
continued long-term monitoring for
arrhythmia after a cryptogenic cerebrovascular
event. Defying what had been long-standing
conventional wisdom, percutaneous coronary
intervention (PCI) of ‘‘non-culprit’’ stable
lesions in addition to immediate PCI of the
infarct-related lesion was shown in two small
studies to improve long-term outcomes. These
findings resulted in a 180 turn in PCI
guidelines and was rapidly incorporated into
clinical practice, however the results of a larger
trial are eagerly awaited to support this turn.
Lastly, the DAPT (ClinicalTrials.gov
NCT01106534) trial showed that extended
therapy with two oral antiplatelet drugs
beyond the usual 12 months post stenting was
associated with reduction in very late stent
thrombosis and recurrent myocardial
infarction, albeit with an increase in bleeding.
Looking ahead to 2015, we anticipate a
similar number of breakthroughs. Ongoing
studies with 3 PCSK9 inhibitors will likely
continue to bang a steady and increasingly
louder drumbeat. We will learn more about
extended duration of dual antiplatelet therapy
with ticagrelor ? aspirin when the PEGASUS-
TIMI 54 (ClinicalTrails.gov NCT01225562) trial
reports this spring. Several drugs targeting
different mechanisms to treat diabetes are
being studied and hold promise to be the first
since metformin to reduce cardiovascular
events. Ongoing research with percutaneous
approaches for treating valvular disease and
renovascular hypertension are also likely to
make big news in 2015, whether the results
are favorable or not. In patients with aortic
stenosis the interventional approach (TAVI) is
likely to become the standard of care, not only
in patients with high surgical risk but in
patients with intermediate risk as well.
Given the enormous number of analyses that
clinical studies and databases generate, a wide
variety of opportunities to publish the results is
required. We hope that many of you will not
only look at Cardiology and Therapy to learn
about these advances, but also encourage you to
submit your best work to the journal for
consideration.
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